Welcome to the Lilly Scientific Information Page for ADA 2026
American Diabetes Association
New Orleans, LA
Quicklinks
See how Lilly supports external requests for provision of study drug and/or financial support
To stay informed on the latest science and innovation, please be sure to follow us on Twitter/X
To stay informed on the latest science and innovation from Lilly Medical, please be sure to follow us on LinkedIn
Disclosures
FRIDAY
- Disease State: Cardiovascular
- Presented by: David D'Alessio
- Molecule(s): Tirzepatide
The SURPASS-CVOT Retinopathy Substudy: Retinal Status after Treatment with Tirzepatide or Dulaglutide in Patients with Type 2 Diabetes and Risk for Progressive Retinopathy
Trial(s) Overview:
FRIDAY
- Disease State: Diabetes Mellitus
- Presented by: Petter Bjornstad
- Molecule(s): Tirzepatide
Reduction in Glomerular Hyperfiltration with Tirzepatide in Youth-Onset T2D
Trial(s) Overview:
SATURDAY
- Disease State: Diabetes Mellitus
- Presented by: Athena Philis-Tsimikas
- Molecule(s): Insulin Efsitora Alfa
Hospitalizations and Outcomes in Adults with Type 2 Diabetes (T2D) Treated with Weekly Insulin Efsitora Alfa (Efsitora): Results from the QWINT Program
Trial(s) Overview:
SATURDAY
- Disease State: Diabetes Mellitus
- Presented by: Grazia Aleppo
- Molecule(s): Insulin Efsitora Alfa
CGM Data Provides Weekly Insulin Efsitora Dose Guidance Equivalent to the Current Standard of FBG and Hypoglycemia Events for T2D Basal Experienced Adults - A Retrospective Analysis
Trial(s) Overview:
SATURDAY
SATURDAY
- Disease State: Diabetes Mellitus
- Presented by: Alice Cheng
- Molecule(s): Insulin Efsitora Alfa
Post-hoc Analysis of Efficacy and Safety Outcomes of Efsitora vs Once-Daily Insulin in Type 2 Diabetes by GLP-1 RA Use Across QWINT-1-4 Trials
Trial(s) Overview:
SATURDAY
- Disease State: Obesity
- Presented by: Ania Jastreboff
- Molecule(s): Retatrutide
The First Phase 3 Obesity Study of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist, in People with Obesity (TRIUMPH-1)
Trial(s) Overview:
SATURDAY
- Disease State: Diabetes Mellitus
- Presented by: Harpreet S. Bajaj
- Molecule(s): Retatrutide
Results of the First Phase 3 Study of Retatrutide in Participants with Type 2 Diabetes (TRANSCEND-T2D-1)
Trial(s) Overview:
SUNDAY
SUNDAY
- Disease State: Obesity
- Presented by: Carol Wysham
- Molecule(s): Orforglipron
Orforglipron and Markers of Insulin Sensitivity and Beta-Cell Function by Prediabetes Status in Adults with Obesity: A Post-Hoc Analysis of the ATTAIN-1 Trial
Trial(s) Overview:
SUNDAY
- Disease State: Cardiovascular
- Presented by: Kristina Secnik Boye
- Molecule(s): Tirzepatide
Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial
Trial(s) Overview:
SUNDAY
SUNDAY
- Disease State: Diabetes Mellitus
- Presented by: Kristina Secnik Boye
- Molecule(s): Tirzepatide
Patient-Reported Outcomes in Adults Initiating Treatment with Tirzepatide or Intensified Conventional Care Early in the Course of T2D: Results After 2 Years of Treatment in SURPASS-EARLY
Trial(s) Overview:
SUNDAY
- Disease State: Diabetes Mellitus
- Presented by: Kendra Terrell
- Molecule(s): Orforglipron
Health-Related Quality of Life (HRQoL) in People with Type 2 Diabetes (T2D) Receiving the Once-Daily, Oral, Non-Peptide GLP-1 RA Orforglipron in ACHIEVE-2 and -3
Trial(s) Overview:
SUNDAY
- Disease State: Obesity
- Presented by: Hunter Hoffmann
- Molecule(s): Orforglipron
Menopausal Stage and Weight Outcomes with Orforglipron vs Placebo: Post-Hoc Subgroup Analysis from ATTAIN-1 and ATTAIN-2
Trial(s) Overview:
SUNDAY
- Disease State: Obesity
- Presented by: Melissa Thomas
- Molecule(s): Mazdutide
Mazdutide Improves Markers of Insulin Sensitivity in Adults with Obesity without T2D
Trial(s) Overview:
SUNDAY
SUNDAY
SUNDAY
SUNDAY
- Disease State: Obesity
- Presented by: Stanley Hsia
- Molecule(s): Mazdutide
Effect of Mazdutide on Kidney Function in People With Obesity or Overweight
Trial(s) Overview:
MONDAY
- Disease State: Obesity
- Presented by: Shobha N Bhattachar
- Molecule(s): Orforglipron
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orforglipron: A Multiple Dose Titration Study in Chinese Participants with Obesity or Overweight with Weight-Related Comorbidities
Trial(s) Overview:
MONDAY
- Disease State: Diabetes Mellitus
- Presented by: Michelle Welch
- Molecule(s): Orforglipron
Orforglipron Compared with Dapagliflozin in Type 2 Diabetes: Results from ACHIEVE-2
Trial(s) Overview:
MONDAY
- Disease State: Diabetes Mellitus
- Presented by: Julio Rosenstock
- Molecule(s): Orforglipron
Orforglipron Compared with Oral Semaglutide in Type 2 Diabetes: Results from ACHIEVE-3
Trial(s) Overview:
MONDAY
- Disease State: Diabetes Mellitus
- Presented by: Francesco Giorgino
- Molecule(s): Orforglipron
Orforglipron Compared with Placebo as an Add-On to Titrated Insulin Glargine: Results From ACHIEVE-5
Trial(s) Overview:
MONDAY
- Disease State: Diabetes Mellitus
- Presented by: Richard Bergenstal
- Molecule(s): Insulin Efsitora Alfa
CGM Data Provides Weekly Insulin Efsitora Dose Guidance Equivalent to the Current Standard of FBG and Hypoglycemia Events for T2D Insulin Naïve Adults- A Retrospective Analysis
Trial(s) Overview:
To receive the latest science and innovation from LillyMedical, be sure to follow us via our Twitter handle @LillyMedical. See our community guidelines.
Contact Us
Call us
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)